



ASX and MEDIA Announcement

MEDLAB RECEIVES NASDAQ SYMBOL RESERVATION AND PROGRESSES NASDAQ DUAL LISTING

Sydney, September 28, 2022 - Medlab Clinical Ltd (ASX:MDC) (Medlab, the Company), an Australian biotech using delivery technology to enhance medicines effectiveness, is pleased to announce the Company has filed with the three key US approval bodies: FINRA, SEC, and NASDAQ, and has subsequently commenced clearing comments.

Secondly, the Company is excited to announce the NASDAQ symbol reserved for Medlab being **NASDAQ: MDLB**. Once Medlab lists on NASDAQ, the Company will be DUAL listed with ASX.

- ENDS -

Authorisation & Additional information

This announcement was authorised by the Board of Directors of Medlab Clinical Limited.

About Medlab Clinical:

Medlab Clinical LTD (ASX:MDC) is pioneering the use of NanoCelle® a proprietary, patented delivery technology using water soluble nanoparticles®, allowing for enhanced medical properties, including increased efficacy, safety, patient compliance and stability.

Medlab's investigative drug pipeline comprises several small and large molecules from repurposing generic medicines to enhancing the delivery of immunotherapies.

Patented lead drug candidate NanaBis™ is being developed for cancer bone pain as a viable alternative to opioid use. Data to date, strongly suggests NanaBis™ may be equally effective in non-cancer neuropathic pain. Medlab operates in Australia (Head Office), USA, and the UK.

For more information, please visit www.medlab.co

Medlab – *better medicines, better patient care*

For further information contact:

Dr. Sean Hall, CEO, Medlab Clinical Ltd

T: +61 411 603 378

E: sean_hall@medlab.co